Fig. 5.

RDX8940 acts synergistically with a dipeptidyl peptidase-4 inhibitor to increase plasma levels of aGLP-1 (A) and tGLP-1 (B) in mice fed a Western diet (nonalcoholic fatty liver disease model), improving glycemic control (C) and insulin sensitivity (D). Bars show mean values; error bars show standard error of the mean (n = 9 or 10 per group). All mice were fed a Western diet except for the lean group. End points were measured in fasted mice 7–8 h post-dose on day 29 of treatment unless otherwise stated. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 vs. Western diet vehicle. aGLP-1, active glucagon-like peptide-1; b.i.d., twice daily; q.d., once daily; sc, subcutaneous; tGLP-1, total glucagon-like peptide-1.